

Dr. C. M. Gupta, FNA, FaSc, FNASc, FAMS, FTWAS


DBT Distinguished Research Professor

and

Former Director, CSIR-IMTECH, Chd; CSIR-CDRI, Lko

CERTIFICATE BY THE NOMINATOR

This is to certify that the above information given by **Dr. M. Owais** is correct. I recommend him for consideration for the “**Sun Pharma Research Foundation Award 2023**” in pharmaceutical sciences. The proposed research work has not been considered for award from any other agency.


(C. M. GUPTA)

Dr. C.M. Gupta FNA, FNASc.
Ex. Director & DBT Distinguished Professor
Central Drug Research Institute
Lucknow-1

Citation

Dr. Mohammad Owais has made significant contributions to the area of design and development of novel delivery systems for drugs and vaccines specifically for treatment of infectious diseases and cancer. Also, he has developed nanoparticles based DNA and subunit vaccines for specific targeting to dendritic cells. Besides, he has shown that pre-exposure of PBMCs with HIV-1 makes the cells resistant to subsequent challenge with HIV-2.

A handwritten signature in dark ink, appearing to read 'Dr. CM Gupta', with a horizontal line underneath.

(Dr. CM Gupta)

Dr. C. M. Gupta, FNA, FaSc, FNASc, FAMS, FTWAS


DBT Distinguished Research Professor

and

Former Director, CSIR-IMTECH, Chd; CSIR-CDRI, Lko

It is my pleasure to nominate **Dr. M. Owais** for the “**Sun Pharma Research Foundation Award 2023**” in pharmaceutical sciences. Dr. Owais has significantly contributed to the targeted drug delivery and nano vaccines against some important infectious diseases. He has recently developed an effective drug formulation for the treatment of COVID-19 disease. The program was sponsored by the Ministry of AYUSH. The as-developed formulation was found to be successful in the treatment of moderate COVID-19 infection in the clinical setup. The proposed research work has not been considered for an award from any other agency.

In spite of their widely acclaimed potential for sustained drug release and potential to accumulate at the desired site, Nanoparticles do come across with series of barriers that prevent the achievement of desirable therapeutic outcomes. The main emphasis of Dr. Owais has therefore been on addressing some of such problems. He has developed siRNA/CRISPR/Cas 9 bearing nanoparticles for the treatment of skin, liver, breast, and lung cancer in model animals. He demonstrated that liposomes prepared with lipids (from *E. coli* or Archaeobacteria) can specifically prime dendritic cells to activate both CD4⁺ T helper as well as CD8⁺ T cytotoxic cells of the host. He has also demonstrated that exosomes, as well as in-side-out erythrocyte vesicles, can deliver encapsulated antigens to the cytoplasm of the target cells and find application in the development of a prophylactic vaccine against murine malaria. Recently, he demonstrated that **nano-particle/amyloid** mediated targeting of RD9 gene products of *Mycobacterium sps* to dendritic cells favors the Th1 phenotype of elicited CD4⁺ T lymphocytes against tuberculosis, thereby helping to cut down the antigen dose by several folds. Besides, he developed nanoparticles-based DNA (SOD/IL-18) and L7/L12 ribosomal protein-bearing vaccines against experimental brucellosis and escheriosome-based subunit vaccines against experimental malaria and leishmaniasis in BALB/c mice.


(C. M. GUPTA)

Dr. C.M. Gupta FNA, FNASc.
Ex. Director & DBT Distinguished Professor
Central Drug Research Institute
Lucknow-1